

## Literatur für onkologie heute 11/2021

### SCHWERPUNKT: Multiples Myelom

#### Therapieoptionen beim refraktären und rezidierten Multiplen Myelom (S. 26–33)

L. Ebinger, M.-S. Raab, C. Khandanpour

1. Palumbo A *et al.* Revised international staging system for multiple myeloma: A report from international myeloma working group. *J Clin Oncol* 2015; 33(26): 2863–69
2. Nijhof IS *et al.* Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update. *Drugs* 2018; 78(1): 19–37
3. Bazarbachi AH *et al.* Relapsed refractory multiple myeloma: a comprehensive overview. *Leukemia* 2019; 33(10): 2343–57
4. Dimopoulos MA *et al.* Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2021; 32(3): 309–22
5. Giralt S *et al.* American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. *Biol Blood Marrow Transplant* 2015; 21(12): 2039–51
6. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. *Am J Hematol* 2020; 95(5): 548–67
7. Holstein SA, and McCarthy PL. Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience. *Drugs* 2017; 77(5): 505–20
8. Weber D *et al.* Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America. *NEngl J Med* 2007; 357(21): 2133–42
9. Gay F *et al.* Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. *Blood* 2010; 115(7): 1343–50
10. Rajkumar SV, and Kumar S. Multiple myeloma current treatment algorithms. *Blood Cancer J* 2020; 10(9): 94
11. Miguel JS *et al.* Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial. *Lancet Oncol* 2013; 14(11): 1055–66
12. Dimopoulos MA *et al.* Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): A phase 3b study in refractory multiple myeloma. *Blood* 2016; 128(4): 497–503
13. Attal M *et al.* Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. *Lancet* 2019; 394(10214): 2096–107
14. Dimopoulos MA *et al.* Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. *Lancet Oncol* 2021; 22(6): 801–12

15. Richardson PG *et al.* Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. *Lancet Oncol* 2019; 20(6): pp. 781–94
16. Obeng EA *et al.* Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. *Blood* 2006; 107(12): 4907–16
17. Richardson PG *et al.* A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma. *N Engl J Med* 2003; 348(26): 2609–17
18. Sonneveld P *et al.* Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. *Blood* 2016; 127(24): 2955–62
19. Montefusco V *et al.* Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse. *Br J Haematol* 2020; 188(6): 907–17
20. Stewart AK *et al.* Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. *N Engl J Med* 2015; 372(2): 142–52
21. Dimopoulos MA *et al.* Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): A randomised, phase 3, open-label, multicentre study. *Lancet Oncol* 2016; 17(1): 27–38
22. Dimopoulos M *et al.* Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. *Lancet* 2020; 396(10245): 186–9723. Moreau P *et al.* Oral ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. *N Engl J Med* 2016; 374(17): 1621–34.
24. Terpos E *et al.* Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. *Ann Hematol* 2020; 99(5): 1049–61
25. Dimopoulos MA *et al.* Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. *J Clin Oncol* 2020; 38: 4030–41
26. Weiner GJ. Building better monoclonal antibody-based therapeutics. *Nat Rev Cancer* 2015; 15(6): 361–70
27. Lonial S *et al.* Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial. *Lancet* 2016; 387(10027): 1551–60
28. Palumbo A *et al.* Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. *N Engl J Med* 2016; 375(8): 754–66
29. Moreau P *et al.* Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. *Lancet* 2021; 397(10292): 2361–71
30. Lonial S *et al.* Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. *N Engl J Med* 2015; 373(7): 621–31
31. Dimopoulos MA *et al.* Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. *Blood Cancer J* 2020; 10(9): 91
32. Dimopoulos MA *et al.* Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. *N Engl J Med* 2018; 379(19): 1811–22

33. Lonial S *et al.* Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. *Lancet Oncol* 2020; 21(2): 207–21
34. Chari A *et al.* Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma. *N Engl J Med* 2019; 381(8): 727–38
35. Kumar SK *et al.* Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. *Lancet Oncol* 2020; 21(12): 1630–42
36. Topp MS *et al.* Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. *J Clin Oncol* 2020; 38: 775–83
37. Harrison SJ *et al.* A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM). *ASH*, Dec. 2020, Accessed: Apr. 30, 2021. [Online]. Available: <https://ash.confex.com/ash/2020/webprogram/Paper134063.html>
38. Verkleij CPM *et al.* T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma. *Oncotarget* 2020; 11(45): 4076–81
39. Chari A *et al.* A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM). *Blood* 2020; 136(Suppl 1): 40–41

---

## PHARMAFORUM

### Rezidiertes und refraktäres Multiples Myelom: Effektive Therapieregime mit Isatuximab (S. 56-57)

1. Fachinformation Sarclisa®, Stand Juni 2021
2. Moreau P *et al.* *Lancet* 2021 Jun 4; doi:10.1016/S0140-6736(21)00592-4

---

## PHARMAFORUM

### Die orale Erhaltungstherapie setzt neue Maßstäbe: Einzigartiges Wirksamkeitsprofil von ONUREG® sorgt für klaren Überlebensvorteil bei verschiedenen AML-Subtypen (S. 58)

1. Fachinformation ONUREG, aktueller Stand
2. Wei AH *et al.* *N Engl J Med* 2020; 383: 2526–37
3. Burnett AK *et al.* *Leukemia* 2017; 31: 310–17
4. Rashidi A *et al.* *Blood* 2016; 128(6): 763–73
5. Savona MR *et al.* *Am J Hematol* 2018; 93(10): 1199–206
6. Streseman C *et al.* *Mol Cancer Ther* 2008; 7: 2998–3005
7. Hollenbach PW *et al.* *PLoS One* 2010; 5(2): e9001
8. Scott LJ. *Drugs* 2016; 76(8): 889–900
9. Streseman C *et al.* *Int J Cancer* 2008; 123(1): 8–13
10. Aimuwu J *et al.* *Blood* 2012; 119(22): 5229–38
11. Laille E *et al.* *PLoS One* 2015; 10(8): e0135520
12. Garcia-Manero G *et al.* *Leukemia* 2016; 30(4): 889–89
13. Fachinformation VIDAZA, aktueller Stand